COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00851162
Recruitment Status : Withdrawn (Study was not continued due to lack of enrollment.)
First Posted : February 25, 2009
Last Update Posted : November 28, 2012
Information provided by (Responsible Party):
Shervin Oskouei, Emory University

Brief Summary:
The purpose of this study is to determine whether using mesenchymal stem cells will heal benign bone lesion defects faster than demineralized bone matrix

Condition or disease Intervention/treatment Phase
Bone Neoplasms Biological: Trinity multipotent stem cells Biological: Demineralized bone matrix(DBM) Phase 2 Phase 3

Detailed Description:

Orthobiologics have recently become a mainstay in treating bony defects whether related to trauma, tumor, or other various reconstructive entities.1 Historically, benign bone growths that were excised, would be filled with either cement, autograft bone, or allograft substances. More recently, other substances have been utilized. These substances carry any or all osteoinductive, osteoconductive, or osteogenic properties. Various materials have been used to fill bony voids specifically related to benign bone growths. Trinity™ by Blackstone Medical inc. is an allograft substance that has recently began utilization. The difference in Trinity compared to various other allografts is that it utilizes mesenchymal stem cells (MSC) along with an allograft carrier to incorporate and induce bone formation. Previously, in order for stem cells to be included in grafting, it would require bone marrow aspiration and the morbidity that is associated with iliac crest bone grafting.

Trinity MSC's are pre-immunodepleted and therefore, do not stimulate local T-cell proliferation but instead are activated to act as osteoblasts and stimulate bone formation. This local response, could accelerate healing, earlier weight-bearing, healing, and filing of bone voids in patients that have had excision of bony masses. In previous animal models, the use of MSC's have been shown to increase bone healing in critical sized defects.

Trinity is currently approved for FDA use in bone defects specifically within the spine or trauma. It has not been shown to have any significant adverse events over standard bone substitute products. We hypothesize benign bone lesions that undergo curettage and filling with Trinity will heal faster than bone lesions filled with basic bone grafting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
Study Start Date : March 2009
Estimated Primary Completion Date : March 2010
Estimated Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Trinity
Trinity multipotent stem cells
Biological: Trinity multipotent stem cells
Enough to fill voids which vary in size

Active Comparator: Demineralized bone matrix
Demineralized bone matrix
Biological: Demineralized bone matrix(DBM)
Enough DBM to fill a bone void defect
Other Name: Grafton

Primary Outcome Measures :
  1. Time to fill bony defect [ Time Frame: Two to 52 weeks ]

Secondary Outcome Measures :
  1. Adverse reaction from bone graft [ Time Frame: Immediately after surgery to one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   11 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages > 11 years
  • Benign bone lesion

Exclusion Criteria:

  • Previous surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00851162

Layout table for location information
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30306
Sponsors and Collaborators
Emory University
Layout table for investigator information
Principal Investigator: Shervin Oskouei, MD Emory University Department of Orthopaedics
Layout table for additonal information
Responsible Party: Shervin Oskouei, MD, Emory University Identifier: NCT00851162    
Other Study ID Numbers: IRB00009762
First Posted: February 25, 2009    Key Record Dates
Last Update Posted: November 28, 2012
Last Verified: November 2012
Keywords provided by Shervin Oskouei, Emory University:
Bone defect
Benign bone lesions
Stem cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases